Drug Trial News

RSS

ChAdOx1 nCoV-19 offers less protection against South African SARS-CoV-2 variant

The results of a double-blind, randomized, multisite placebo-controlled trial that was conducted in South Africa show that Oxford’s ChAdOx1 nCoV-19 (AZD1222) vaccine has no efficacy against the B.1.351 variant in preventing mild-to-moderate coronavirus disease 2019 (COVID-19), and shows reduced neutralization properties of developed antibodies. The findings are published in the New England Journal of Medicine.

21 Mar 2021

VHIO-born spin-off receives approval to initiate Phase I/II clinical trial of novel Myc inhibitor

Co-founded back in 2014 by VHIO's Laura Soucek, CEO of the enterprise, and Marie-Eve Beaulieu, Chief Scientific Officer (CSO) of the company, VHIO-born spin-off Peptomyc S.L. has just announced that it has received approval from the Spanish Agency of Medicines and Medical Devices for conducting clinical trials in Spain (AEMPS), to initiate the first-in-human Phase I/II clinical trial with its first compound - a disruptive Myc inhibitor, Omomyc (OMO-103).

19 Mar 2021

Anti-SARS-CoV-2 drug candidate enters phase I clinical trial

DC402234 (FB2001), an anti-SARS-CoV-2 drug candidate mainly developed by research team at the Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of Sciences enters its Phase I clinical trial in the United States on March 15.

19 Mar 2021

Novel cancer-fighting gene therapy enters phase I clinical trial

Researchers from the MDC and Charité have developed a new gene therapy based around a special T-cell receptor that helps the immune system effectively recognize and fight cancer cells.

18 Mar 2021

Phase 3 DREAM3R trial opens for malignant pleural mesothelioma

The DREAM3R phase three clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand.

17 Mar 2021

Evaluation of Pfizer-BioNTech COVID-19 vaccine among residents of two skilled nursing facilities

The severity of COVID-19 among the residents of long-term care facilities (LTCFs) has been reported to be disproportionately high. Specifically, individuals residing in skilled nursing facilities (SNFs) are found to be the most severely affected, both in terms of morbidity and mortality, and are, thereby, listed for early COVID-19 vaccination. In comparison to the general population, SNF residents are more vulnerable, with a weak immune system.

17 Mar 2021

Testing for mRNA-1283, Moderna's next generation COVID-19 vaccine commences

As vaccine efforts against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease, roll out in various countries, Moderna ups the game by testing its next-generation COVID-19 vaccine.

16 Mar 2021

Chimeric vaccines may provide universal protection against viruses like SARS-CoV-2

Researchers in the United States have developed “chimeric” vaccines that provided cross-protection against different strains of sarbecovirus in mice, including the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).

15 Mar 2021

New Phase 1 study evaluates prime/boost HIV-1 vaccine formulated with combinations of adjuvants

A new Phase 1 vaccine study began today that will evaluate experimental prime/boost HIV-1 vaccine regimens formulated with combinations of different adjuvants, including one from the Army Liposome Formulation (ALF) family of adjuvants developed by scientists with the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research.

15 Mar 2021

Henry Ford Cancer Institute launches new initiative to improve minority participation in clinical trials

Henry Ford Cancer Institute is launching the Participatory Action for Access to Clinical Trials (PAACT) project to dramatically improve the representation of the African American community and other minorities in cancer clinical trials.

11 Mar 2021

Nanobody works against all SARS-CoV-2 variants of concern in animal model

Researchers based in Belgium have developed a new antibody drug that is highly successful at neutralizing coronavirus disease 2019 (COVID-19) in Syrian hamsters. The new biologic was administered to the rodents and was found to be equally successful at neutralizing the original severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain, and also the new mutant variants, such as the South African and UK strains.

11 Mar 2021

South African SARS-CoV-2 variant most problematic for BNT-162b2 vaccine

Researchers from Germany and the US investigated the efficacy of neutralizing antibodies against newer variants using serum and saliva samples obtained from groups of infected, vaccinated (with Pfizer BNT-162b2), and uninfected individuals. The researchers started this study to uncover vaccine-induced immune response and show the efficiency of antibody binding and neutralization in SARS-CoV-2 variants.

10 Mar 2021

Hydroxychloroquine has no effect in treating people with COVID-19, study shows

A year ago, infectious disease doctor Christine Johnston was leading a study on the use of hydroxychloroquine for the treatment of people with COVID-19.

10 Mar 2021

FDA qualifies C-Path’s DIBSS-C for clinical trials

Critical Path Institute's (C-Path) Patient-Reported Outcome (PRO) Consortium announces the qualification of the Diary for Irritable Bowel Syndrome Symptoms-Constipation (DIBSS-C) by the U.S. Food and Drug Administration (FDA).

10 Mar 2021

Phase 2 clinical trial is now open at Columbia to test gene therapy for dry macular degeneration

A phase 2 clinical trial is underway at Columbia University and NewYork-Presbyterian to test an investigational gene therapy for dry age-related macular degeneration, a progressive, chronic eye disease with no cure and a leading cause of blindness in the United States.

9 Mar 2021

COVID-19 vaccine candidate approved for human clinical testing

A few days from now the first human will be vaccinated with a Danish vaccine candidate against COVID-19.

9 Mar 2021

Two doses of Pfizer-BioNTech SARS-CoV-2 vaccine induce humoral protection against U.K. and S.A. variants

Researchers at the Pitié Salpêtrière Hospital, Department of Virology, Paris, France determined that in BNT162b2-vaccinated participants who received two doses, their sera harbored at least a neutralizing titer against the three SARS-CoV-2 variants.

8 Mar 2021

Self-assembling nanoparticles an effective vaccine candidate for SARS-CoV-2

The currently developed vaccines against SARS-CoV-2 include the RBD in their immunogen. With a similar objective, a new study developed an RBD protein-based vaccine candidate against the SARS-CoV-2, using self-assembling Helicobacter pylori-bullfrog ferritin nanoparticles as an antigen delivery system. The study is published recently in the journal mBio (by the American Society of Microbiology).

8 Mar 2021

CAR T-cell therapy triples expected length of remission for relapsed multiple myeloma patients

A new type of CAR T-cell therapy more than triples the expected length of remission for multiple myeloma patients who have relapsed several times, according to an international clinical trial with UT Southwestern as the lead enrolling site.

8 Mar 2021

Clinical trial launched to test the effectiveness of mouthwash in reducing COVID-19 spread

Researchers at the University of North Carolina at Chapel Hill Adams School of Dentistry have launched a clinical trial to test whether mouthwash can reduce a person's risk of spreading coronavirus.

8 Mar 2021

Previous
1
...
55
56
57
58
59
60
61
...
1143
Next

Drug Trial News

ChAdOx1 nCoV-19 offers less protection against South African SARS-CoV-2 variant

VHIO-born spin-off receives approval to initiate Phase I/II clinical trial of novel Myc inhibitor

Anti-SARS-CoV-2 drug candidate enters phase I clinical trial

Novel cancer-fighting gene therapy enters phase I clinical trial

Phase 3 DREAM3R trial opens for malignant pleural mesothelioma

Evaluation of Pfizer-BioNTech COVID-19 vaccine among residents of two skilled nursing facilities

Testing for mRNA-1283, Moderna's next generation COVID-19 vaccine commences

Chimeric vaccines may provide universal protection against viruses like SARS-CoV-2

New Phase 1 study evaluates prime/boost HIV-1 vaccine formulated with combinations of adjuvants

Henry Ford Cancer Institute launches new initiative to improve minority participation in clinical trials

Nanobody works against all SARS-CoV-2 variants of concern in animal model

South African SARS-CoV-2 variant most problematic for BNT-162b2 vaccine

Hydroxychloroquine has no effect in treating people with COVID-19, study shows

FDA qualifies C-Path’s DIBSS-C for clinical trials

Phase 2 clinical trial is now open at Columbia to test gene therapy for dry macular degeneration

COVID-19 vaccine candidate approved for human clinical testing

Two doses of Pfizer-BioNTech SARS-CoV-2 vaccine induce humoral protection against U.K. and S.A. variants

Self-assembling nanoparticles an effective vaccine candidate for SARS-CoV-2

CAR T-cell therapy triples expected length of remission for relapsed multiple myeloma patients

Clinical trial launched to test the effectiveness of mouthwash in reducing COVID-19 spread

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News